HER-RADIO: Increasing Access to Breast Cancer Treatments in Nigeria

mPharma and Roche have launched a groundbreaking service called Her-Radio to increase access to radiotherapy and HER2+ breast cancer treatments in Nigeria. The service is built on our Mutti platform and allows for patients to receive interest free payment plans at the National Hospital in Abuja. mPharma partnered with Roche to create patient profiles based on need to establish payment plan options for Her2+ patients. The baseline payment plan is seen in the example below:

How does it work?

Why is this Important?

Breast Cancer is the most commonly diagnosed cancer for women in Nigeria and is responsible for 16% of cancer related deaths. Nigeria contributed 15% of the estimated 681,000 new cases of cancer in Africa in 2008. A recent report showed that 87%-93% of patients pay out of pocket for their treatments. This limits the average number of cycles for those receiving HER2-targeted therapy to 5 compared to 14 for those with health insurance.

If breast cancer is detected early (Stage 1), the probability of it been cured and surviving beyond 5 years is 95%. We hope that through Her-Radio, more Nigerian women can start treatment early when diagnosed with breast cancer. We will be announcing additional services soon that will help with the early detection of breast cancer.

Call your Mutti Cancer Guide at 0902–713–3852 and let Mutti help you on your journey to good health.